Evan Hall
Medical Oncology · Seattle, WANPI 1306102413
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,340 of the $1,434 with a category attached, or 93.5%. Eisai Inc. accounts for 94.4% of it on its own, with 3 other manufacturers making up the rest. That places this record below the midpoint for medical oncology clinicians in WA, where the typical reported total is $2,355.
Across 7 payments — averaging $204.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$1K
- Merck$40
- Novartis$22
- Pfizer$18
Across 32 payments — averaging $23,834 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$643K
- Merck$93K
- Regeneron$14K
- E.r. Squibb & Sons, L.L.C.$10K
- AstraZeneca$3K
What the payments were for
- Consulting fees$1,34093%
- Food & beverage$363%
- Education$584%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 3 | $1,354 |
| Merck | 2 | $40 |
| Novartis | 1 | $22 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$1,340
How this compares
$1,434 in reported general payments places this provider in the 45th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 22 | $514,398 |
| Hydrocortisone | 13 | $493 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.